This article is more than 5 years old. Information may no longer be current.

Net sales for Eylea increased 24% in 2016

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Regeneron Pharmaceuticals reported U.S. net sales of Eylea increased 15% from $746 million in the fourth quarter of 2015 to $858 million in the fourth quarter of 2016, according to a company press release.

Eylea (aflibercept) net sales for the full year were up 24% to $3.323 billion from $2.676 billion in 2015.

Outside of the U.S., where Bayer commercializes Eylea, quarterly net sales totaled $496 million compared with $413 million in the fourth quarter of 2015. Eylea yearly net sales outside the U.S. were $1.872 billion compared with $1.413 billion in 2015.

Revenues totaled $4.860 billion in 2016, an 18% increase compared with $4.104 billion in 2015.

Yearly GAAP income was $896 million, or $7.70 per diluted share, compared with a GAAP income of $636 million, or $5.52 per diluted share, in 2015.

Praluent (alirocumab), a treatment for elevated low-density lipoprotein cholesterol, had global net sales of $41 million in the fourth quarter of 2016, an increase from $7 million in the same quarter of 2015. Its yearly sales were up from $11 million in 2015 to $116 million in 2016.